{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-22-000104","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2022-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.663510+00:00","generated_at":"2026-06-21T11:10:23.584030+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Context Therapeutics nominates CTIM-76 as lead CLDN6 bispecific; IND expected Q1 2024","bullets":["CTIM-76 is a CLDN6 x CD3 bispecific antibody with silenced Fc to reduce aberrant T-cell activation.","IND submission for CTIM-76 planned for Q1 2024 to the FDA.","Targets CLDN6-positive solid tumors including ovarian, endometrial, testicular, and gastric cancers.","Preclinical data show potent lysis of CLDN6+ cancer cells with minimal free cytokine release.","Collaboration with Integral Molecular; webinar on December 1, 2022, at 11 a.m. ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-22-000104","json":"https://secwatch.observer/filing/0001842952-22-000104.json","markdown":"https://secwatch.observer/filing/0001842952-22-000104.md","text":"https://secwatch.observer/filing/0001842952-22-000104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295222000104/0001842952-22-000104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295222000104/cntx-20221129.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T11:10:23.584030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}